# Romesh Subramanian

> Romesh Subramanian is a scientist, company founder and venture partner at Scion Life Sciences. He co-founded RaNA Therapeutics, later Translate Bio, and Dyne Therapeutics, where he served as president and CEO and chief scientific officer. His career also includes research leadership at Pfizer and Alexion, the presidency and CEO role at Ascidian Therapeutics, and board appointments. Emory recognised him with its GDBBS Distinguished Alumni Award in 2025.

- **Role:** Venture Partner at Scion Life Sciences
- **Organizations:** Scion Life Sciences, Dyne Therapeutics, RaNA Therapeutics (later Translate Bio), Ascidian Therapeutics, Atlas Venture, Alexion Pharmaceuticals, Pfizer, Thrasos Therapeutics, Ceptur Therapeutics, Radar Therapeutics
- **Education:** B.S. in Zoology, Loyola College, M.S. in Biology, Duke University, Ph.D.; Molecular and Systems Pharmacology programme, Emory University
- **Known for:** Co-founded RaNA Therapeutics, which later became Translate Bio; Sanofi acquired Translate Bio in 2021., Co-founded Dyne Therapeutics and served as its founding CEO and chief scientific officer., Led Dyne at its $50 million Series A public launch in April 2019.

## Career timeline

- **2000** — Co-authored a review of 14-3-3 proteins with Haian Fu and Shane C. Masters.
- **2001** — Graduated from Emory with a Ph.D.
- **Before 2011** — Held positions at Thrasos Therapeutics and Pfizer.
- **2011–2014** — Co-founded RaNA Therapeutics and served as senior director.
- **2014–2017** — Senior director of discovery research at Alexion.
- **2017** — Became entrepreneur-in-residence at Atlas Venture in October.
- **2018** — Served as Dyne chief scientific officer from April; president and CEO from November.
- **2019** — Led Dyne at its April public launch with a $50 million Series A; became CSO in October following Joshua Brumm’s CEO appointment.
- **2021** — Stepped down as Dyne CSO on June 2 and transitioned to an advisory role.
- **2022** — Appointed to Ceptur’s board in March; named Ascidian president and CEO at its October launch.
- **2025** — Scion announced his appointment as venture partner on April 17; received Emory GDBBS Distinguished Alumni Award and returned for October 2 seminar.

## Achievements

- Co-founded RaNA Therapeutics, which later became Translate Bio; Sanofi acquired Translate Bio in 2021.
- Co-founded Dyne Therapeutics and served as its founding CEO and chief scientific officer.
- Led Dyne at its $50 million Series A public launch in April 2019.
- Received the 2025 Distinguished Alumni Award from Emory’s Graduate Division of Biological and Biomedical Sciences.

## Latest updates

- **2025-10** — Returned to Emory for the “1,000 Miles” seminar as its 2025 GDBBS Distinguished Alumni Award recipient.
- **2025-04** — Scion Life Sciences announced his appointment as a venture partner to help build its first wave of internally incubated companies.

## Links

- Website: https://www.scionlifesciences.com/team/investment-team/romesh-subramanian-phd
- LinkedIn: https://www.linkedin.com/in/romesh-subramanian-4567132/

---

Profile page: https://yespress.io/romesh-subramanian
Published by YesPress — https://yespress.io
Last updated: 2026-10-27